| A next generation connectivity map: L1000 platform and the first 1,000,000 profiles A Subramanian, R Narayan, SM Corsello, DD Peck, TE Natoli, X Lu, ... Cell 171 (6), 1437-1452. e17, 2017 | 2527 | 2017 |
| KRAS and YAP1 converge to regulate EMT and tumor survival DD Shao, W Xue, EB Krall, A Bhutkar, F Piccioni, X Wang, AC Schinzel, ... Cell 158 (1), 171-184, 2014 | 732 | 2014 |
| Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities KR Sanson, RE Hanna, M Hegde, KF Donovan, C Strand, ME Sullender, ... Nature communications 9 (1), 5416, 2018 | 635 | 2018 |
| A melanocyte lineage program confers resistance to MAP kinase pathway inhibition CM Johannessen, LA Johnson, F Piccioni, A Townes, DT Frederick, ... Nature 504 (7478), 138-142, 2013 | 482 | 2013 |
| Mutational processes shape the landscape of TP53 mutations in human cancer AO Giacomelli, X Yang, RE Lintner, JM McFarland, M Duby, J Kim, ... Nature genetics 50 (10), 1381-1387, 2018 | 391 | 2018 |
| An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia B Knoechel, JE Roderick, KE Williamson, J Zhu, JG Lohr, MJ Cotton, ... Nature genetics 46 (4), 364-370, 2014 | 383 | 2014 |
| A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies S Boettcher, PG Miller, R Sharma, M McConkey, M Leventhal, AV Krivtsov, ... Science 365 (6453), 599-604, 2019 | 304 | 2019 |
| Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies R Guièze, VM Liu, D Rosebrock, AA Jourdain, M Hernández-Sánchez, ... Cancer cell 36 (4), 369-384. e13, 2019 | 263 | 2019 |
| High-throughput phenotyping of lung cancer somatic mutations AH Berger, AN Brooks, X Wu, Y Shrestha, C Chouinard, F Piccioni, ... Cancer cell 30 (2), 214-228, 2016 | 212 | 2016 |
| A functional landscape of resistance to ALK inhibition in lung cancer FH Wilson, CM Johannessen, F Piccioni, P Tamayo, JW Kim, ... Cancer cell 27 (3), 397-408, 2015 | 183 | 2015 |
| Systematic functional interrogation of rare cancer variants identifies oncogenic alleles E Kim, N Ilic, Y Shrestha, L Zou, A Kamburov, C Zhu, X Yang, R Lubonja, ... Cancer discovery 6 (7), 714-726, 2016 | 151 | 2016 |
| Phenotypic characterization of a comprehensive set of MAPK1/ERK2 missense mutants L Brenan, A Andreev, O Cohen, S Pantel, A Kamburov, D Cacchiarelli, ... Cell reports 17 (4), 1171-1183, 2016 | 149 | 2016 |
| Androgen receptor with elongated polyglutamine tract forms aggregates that alter axonal trafficking and mitochondrial distribution in motoneuronal processes F Piccioni, P Pinton, S Simeoni, P Pozzi, U Fascio, G Vismara, L Martini, ... The FASEB Journal 16 (11), 1418-1420, 2002 | 134 | 2002 |
| MAPK15/ERK8 stimulates autophagy by interacting with LC3 and GABARAP proteins D Colecchia, A Strambi, S Sanzone, C Iavarone, M Rossi, C Dall’Armi, ... Autophagy 8 (12), 1724-1740, 2012 | 118 | 2012 |
| A compendium of genetic modifiers of mitochondrial dysfunction reveals intra-organelle buffering TL To, AM Cuadros, H Shah, WHW Hung, Y Li, SH Kim, DHF Rubin, ... Cell 179 (5), 1222-1238. e17, 2019 | 116 | 2019 |
| Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer P Mao, O Cohen, KJ Kowalski, JG Kusiel, JE Buendia-Buendia, ... Clinical Cancer Research 26 (22), 5974-5989, 2020 | 111 | 2020 |
| ATXN1L, CIC, and ETS transcription factors modulate sensitivity to MAPK pathway inhibition B Wang, EB Krall, AJ Aguirre, M Kim, HR Widlund, MB Doshi, E Sicinska, ... Cell reports 18 (6), 1543-1557, 2017 | 108 | 2017 |
| Noncanonical open reading frames encode functional proteins essential for cancer cell survival JR Prensner, OM Enache, V Luria, K Krug, KR Clauser, JM Dempster, ... Nature biotechnology 39 (6), 697-704, 2021 | 97 | 2021 |
| Translational regulation during oogenesis and early development: the cap-poly (A) tail relationship F Piccioni, V Zappavigna, AC Verrotti Comptes rendus biologies 328 (10-11), 863-881, 2005 | 94 | 2005 |
| ER stress signaling promotes the survival of cancer “persister cells” tolerant to EGFR tyrosine kinase inhibitors H Terai, S Kitajima, DS Potter, Y Matsui, LG Quiceno, T Chen, T Kim, ... Cancer research 78 (4), 1044-1057, 2018 | 85 | 2018 |
